DIABETES SGLT2 inhibitors and diabetic ketoacidosis - a growing concern

被引：19

作者：

Umpierrez, Guillermo E. ^{[1
]}

机构：

[1] Emory Univ, Sch Med, Endocrinol Metab & Lipids, 69 Jesse Hill Jr Dr, Atlanta, GA 30303 USA

来源：

NATURE REVIEWS ENDOCRINOLOGY | 2017年 / 13卷 / 08期

基金：

美国国家卫生研究院;

关键词：

COTRANSPORTER; 2; INHIBITOR; CANAGLIFLOZIN; OUTCOMES;

D O I：

10.1038/nrendo.2017.77

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Diabetic ketoacidosis is a worrying complication associated with the use of sodium/glucose cotransporter 2 (SGLT2) inhibitors in patients with type 1 diabetes mellitus (T1DM) or T2DM. A recent analysis of data in the FDA Adverse Event Reporting System by Fadini and colleagues adds to this concern.

引用

页码：441 / 442

页数：2

共 10 条

[1]

[Anonymous], REV DIAB MED CALL SG

[2] Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program [J].

Erondu, Ngozi ;

Desai, Mehul ;

Ways, Kirk ;

Meininger, Gary .

DIABETES CARE, 2015, 38 (09) :1680-1686

[3] SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA Adverse Event Reporting System [J].

Fadini, Gian Paolo ;

Bonora, Benedetta Maria ;

Avogaro, Angelo .

DIABETOLOGIA, 2017, 60 (08) :1385-1389

[4] Case of ketoacidosis by a sodium-glucose cotransporter 2 inhibitor in a diabetic patient with a low-carbohydrate diet [J].

Hayami, Tomohide ;

Kato, Yoshiro ;

Kamiya, Hideki ;

Kondo, Masaki ;

Naito, Ena ;

Sugiura, Yukako ;

Kojima, Chika ;

Sato, Sami ;

Yamada, Yuichiro ;

Kasagi, Rina ;

Ando, Toshihito ;

Noda, Saeko ;

Nakai, Hiromi ;

Takada, Eriko ;

Asano, Emi ;

Motegi, Mikio ;

Watarai, Atsuko ;

Kato, Koichi ;

Nakamura, Jiro .

JOURNAL OF DIABETES INVESTIGATION, 2015, 6 (05) :587-590

[5] Efficacy and Safety of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-on to Insulin in Patients With Type 1 Diabetes [J].

Henry, Robert R. ;

Thakkar, Payal ;

Tong, Cindy ;

Polidori, David ;

Alba, Maria .

DIABETES CARE, 2015, 38 (12) :2258-2265

[6] The Effect of Canagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, on Glycemic End Points Assessed by Continuous Glucose Monitoring and Patient-Reported Outcomes Among People With Type 1 Diabetes [J].

Rodbard, Helena W. ;

Peters, Anne L. ;

Slee, April ;

Cao, Anjun ;

Traina, Shana B. ;

Alba, Maria .

DIABETES CARE, 2017, 40 (02) :171-180

[7] SGLT inhibitors in management of diabetes [J].

Tahrani, Abd A. ;

Barnett, Anthony H. ;

Bailey, Clifford J. .

LANCET DIABETES & ENDOCRINOLOGY, 2013, 1 (02) :140-151

[8]

U. S. Food and Drug Administration, FDA WARNS SGLT2 INH

[9] Diabetic emergencies - ketoacidosis, hyperglycaemic hyperosmolar state and hypoglycaemia [J].

Umpierrez, Guillermo ;

Korytkowski, Mary .

NATURE REVIEWS ENDOCRINOLOGY, 2016, 12 (04) :222-232

[10] Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes [J].

Zinman, Bernard ;

Wanner, Christoph ;

Lachin, John M. ;

Fitchett, David ;

Bluhmki, Erich ;

Hantel, Stefan ;

Mattheus, Michaela ;

Devins, Theresa ;

Johansen, Odd Erik ;

Woerle, Hans J. ;

Broedl, Uli C. ;

Inzucchi, Silvio E. ;

Aizenberg, D. ;

Ulla, M. ;

Waitman, J. ;

De Loredo, L. ;

Farias, J. ;

Fideleff, H. ;

Lagrutta, M. ;

Maldonado, N. ;

Colombo, H. ;

Ferre Pacora, F. ;

Wasserman, A. ;

Maffei, L. ;

Lehman, R. ;

Selvanayagam, J. ;

d'Emden, M. ;

Fasching, P. ;

Paulweber, B. ;

Toplak, H. ;

Luger, A. ;

Drexel, H. ;

Prager, R. ;

Schnack, C. ;

Schernthaner, G. ;

Fliesser-Goerzer, E. ;

Kaser, S. ;

Scheen, A. ;

Van Gaal, L. ;

Hollanders, G. ;

Kockaerts, Y. ;

Capiau, L. ;

Chachati, A. ;

Persu, A. ;

Hermans, M. ;

Vantroyen, D. ;

Vercammen, C. ;

Van de Borne, P. ;

Mathieu, C. ;

Benhalima, K. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (22) :2117-2128

← 1 →